Pediatric Nephrology

Stavudine Efficacy Compared to Zidovudine in ZDV-Pretreated HIV Positive Patient

Published in AIDS Weekly, October 2nd, 1995

Switching to stavudine (also known as d4T, brand name Zerit) was more effective than continuing zidovudine (also known as AZT, brand name Retrovir) at preventing progression to AIDS or death among patients with HIV who had been taking zidovudine for at least six months.

The patients who received stavudine had better immune function (higher CD4 counts), maintained higher weight, and lived slightly longer than those who remained on zidovudine. The drug was very well tolerated. This is the first study showing the clinical efficacy of stavudine, the newest drug licensed by the FDA for the treatment of HIV.

Stavudine was licensed in the summer of 1995...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1995-10-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry